Abbott Laboratories $ABT Shares Sold by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd cut its Abbott (ABT) stake by 75.2% in Q4, selling 26,000 shares and leaving 8,565 shares valued at about $1.07M, while institutional ownership remains roughly 75.18% with large increases from holders like CPP Investment Board.
• Several analysts have lowered price targets on ABT, but the stock maintains a consensus rating of "Moderate Buy" with a mean target of $119.43.
• Abbott slightly beat quarterly estimates (EPS $1.15 vs. $1.14; revenue $11.16B vs. $10.99B), set FY2026 guidance of 5.38–5.58 EPS, and announced a $0.63 quarterly dividend (≈2.9% yield).

S Bank Fund Management Ltd trimmed its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 75.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,565 shares of the healthcare product maker's stock after selling 26,000 shares during the period. S Bank Fund Management Ltd's holdings in Abbott Laboratories were worth $1,073,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC raised its holdings in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares in the last quarter. United Bank increased its position in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC raised its stake in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after purchasing an additional 292,547 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABT has been the subject of several research analyst reports. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating for the company in a report on Wednesday, April 8th. Jefferies Financial Group reduced their target price on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Citigroup lowered their price target on Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating for the company in a report on Friday, April 17th. Oppenheimer dropped their price target on Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Finally, Bank of America decreased their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $119.43.

Insider Activity

In related news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company's stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock valued at $353,097 over the last quarter. Insiders own 0.46% of the company's stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $87.18 on Wednesday. Abbott Laboratories has a one year low of $86.16 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market capitalization of $151.84 billion, a price-to-earnings ratio of 24.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The stock's fifty day moving average is $103.83 and its 200-day moving average is $115.68.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.9%. Abbott Laboratories's dividend payout ratio (DPR) is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.